Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Bayer acquired Monsanto this year for $63 billion. "If we can settle nuisances at some point where the defense costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint," CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling. He added: "We will resolutely and with all means defend ourselves in this (glyphosate) litigation." Baumann was speaking on Monday to German media invited to visit Bayer's new operations in the former research and development facilities of Monsanto in St. Louis, Missouri. The remarks, made on Monday, were embargoed to the end of the week to allow media to return home. Shares in Bayer have lost 25 percent in value since Aug. 10, when a San Francisco jury awarded $289 million to Dewayne Johnson on grounds Monsanto failed to warn the school groundskeeper and other consumers of the cancer risks posed by glyphosate-based RoundUp and Ranger Pro. Johnson has terminal non-Hodgkin's lymphoma that he alleges was caused by the herbicides. A judge later reduced the award to $78 million. Bayer denies that glyphosate causes cancer and says decades of scientific studies and real-world use have shown the chemical to be safe for human use. The company is appealing the findings. The number of glyphosate cases that Bayer faces across the United States has jumped to more than 8,700, prompting concerns among investors about the impact of litigation costs on Bayer's bottom line. Baumann expressed confidence that Bayer could handle the litigation, and cited its "inexpensive" $12 million settlement of 4,000 lawsuits over its contraceptive Mirena device. Bayer also won five of six trials over its best-selling bloodthinner Xarelto, over which it faces 24,000 U.S. lawsuits. The sixth jury found in favor of a plaintiff, but a judge later overturned the decision. "Due to our exposure as a pharmaceutical company, we have the experience to defend those (glyphosate) cases," he said. Baumann said the company's legal strategy had been revised following the integration of Bayer and Monsanto in mid-August. He declined to provide details, but recent court filings reveal some of the steps the company has taken. Last week, Bayer added the attorneys from law firm Arnold & Portner who won the Xarelto cases for the company to its glyphosate defense team. It is also trying to change the juror selection process for upcoming trials. In filings last week in San Francisco federal court, where a new glyphosate trial is scheduled to begin on Feb. 25, 2019, Bayer said the "jury pool likely has grown more hostile" due to negative media coverage following the Johnson verdict. Michael Miller, one of the attorneys for the plaintiff, said the company's claims were "hypocritical beyond belief" given its own efforts to control the message on glyphosate, most recently in a full-page advertisement in the Washington Post. Bayer has asked U.S. District Judge Vince Chhabria, who is overseeing the San Francisco case and some 580 others, to significantly expand the jury pool and question prospective jurors about their knowledge of the media coverage of the cases. Chhabria is expected to decide on the requests in December.
[A]: Bayer CEO says would consider glyphosate settlement depending on costs.

[Q]: One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves in one case, with treatment just twice a year. The research was featured at an American Heart Association conference ending Monday in Philadelphia. "There's a lot of excitement" about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles. Scientists have been exploring gene therapy altering DNA to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania's Dr. Daniel Rader, who has consulted for some makers of these drugs. The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these "RNA-interference" drugs recently were approved for other conditions, and research is also targeting heart disease. Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months. The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran's maker, The Medicines Company, plans to seek federal approval for it later this year. Two other RNA interference drugs aim at a different target triglycerides, another fat in the blood that's elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed. Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs. Other research found new benefits from older drugs. AstraZeneca's Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects. Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine sold as Colcrys, Mitigare and in generic form was tested in 4,745 people who recently had a heart attack. After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths. Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine. Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive. "When you have a safe drug that's easily available, it's going to be hard to hold this one back," he said. ___ Marilynn Marchione can be followed on Twitter at http://twitter.com/MMarchioneAP ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
[A]: New, old drugs may offer fresh ways to fight heart disease.

[Q]: About 1.3 million people worldwide died of TB in 2017. A further 300,000 people with both HIV and TB died in last year, according to World Health Organization figures released this month. Once referred to as 'consumption' because of the way sufferers appear to waste away, tuberculosis has been known for centuries. The bacterium responsible for TB was discovered 136 years ago and the development of an effective antibiotic helped rich countries to largely contain the disease after World War II. Still, the U.N. health agency estimates that about 10 million people worldwide become newly infected with TB each year, mostly in poor countries where access to health care is limited. "It really is a global epidemic," said Dr. Tereza Kasaeva, who heads WHO's program to combat TB. Speaking ahead of a high-level meeting on the sidelines of the U.N. General Assembly, Kasaeva said the U.N.'s target of eradicating tuberculosis worldwide by 2030 "is very ambitious given that for now progress is too slow." Like HIV, tuberculosis remains a highly stigmatized illness, preventing some sufferers from seeking treatment. Experts are particularly concerned about the rising number of people contracting drug-resistant variants of TB, many of which aren't diagnosed properly. Treating them can be costly and arduous, requiring years of medication with strong side effects. Dr. Ralf Otto-Knapp of the German Central Committee to Combat Tuberculosis, a group established in the late 19th century when the disease was still widespread in much of Europe, warned against complacency about the disease in an age of global travel. "Because of the increasing mobility in society it also affects economically more powerful countries," he said. "We need a joint political will and the necessary resources to fight tuberculosis effectively." Kasaeva said she hoped leaders attending the New York meeting Wednesday will commit to closing the growing gap between the amount of money available and the billions more required to tackle the disease. Campaigners applauded a recent decision by the World Health Organization to recommend a change in the way drug-resistant tuberculosis is treated, prioritizing oral drugs over injectable medication. The group Doctors Without Borders said such treatment can reduce debilitating side effects, help improve cure rates and cut the number of deaths, but noted that it requires U.S. pharmaceutical giant Johnson & Johnson, which makes the key drug bedaquiline, to reduce its price in low- and middle-income countries with high rates of drug-resistant TB. The company has already sharply reduced costs for the drug in some countries, but in others a six-month course of treatment can cost several thousand dollars far more than most people can afford. Companies have been reluctant to invest in developing TB medication with only two new drugs coming onto the market in the past 50 years.
[A]:
Governments to discuss tackling tuberculosis at UN summit.